- Home
- BOOT vs AXSM Comparison
BOOT vs AXSM Comparison
Compare BOOT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOOT | AXSM |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 10.4B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BOOT | AXSM |
|---|---|---|
| Price | $129.21 | $203.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $223.09 | $211.12 |
| AVG Volume (30 Days) | ★ 594.8K | 497.9K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.00 | ★ 38.56 |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $776,854,000.00 | N/A |
| Revenue This Year | $19.98 | $57.24 |
| Revenue Next Year | $13.91 | $55.88 |
| P/E Ratio | $54.29 | ★ N/A |
| Revenue Growth | ★ 14.59 | N/A |
| 52 Week Low | $120.64 | $115.44 |
| 52 Week High | $210.25 | $260.19 |
Technical Indicators
Market Signals| Indicator | BOOT | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 44.51 |
| Support Level | N/A | $197.05 |
| Resistance Level | $169.60 | $225.16 |
| Average True Range (ATR) | 5.62 | 7.51 |
| MACD | -1.98 | 0.31 |
| Stochastic Oscillator | 22.90 | 14.12 |
Price Performance
Historical ComparisonAbout BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.